Immunotherapy Treatment Impacted By Covid-19
- The data to develop guidance around treatment for cancer during Covid-19 is extremely early and uncertain
- Physicians are not entirely sure how immunotherapy drugs will interact with Covid-19
- You should consult your physician on whether to go ahead with treatment, and possibly get multiple opinions
“We really don’t know what the interaction of (immunotherapy) is going to be with the virus,” Dr. Brendon Stiles, a thoracic surgeon at Weill Cornell Medicine, tells SurvivorNet. “You could probably argue both ways that it may completely throw your immune system out of whack and predispose you to infection [or] maybe because you’re getting an immune stimulus, you might be able to fight off viruses better. We’re going to need a lot more data to understand that better.”
Read MoreImmunotherapy In Lung Cancer Treatment
Immunotherapy treatment marks a revolution in lung cancer care. The new class of immunotherapy drugs, also known as checkpoint inhibitors, have had encouraging survival rates when used by lung cancer patients.
In a separate interview with SurvivorNet, Dr. Stiles says that some late stage cancer patients have benefited from immunotherapy treatment without chemotherapy being involved.
"If you have high expression of a protein that we know is targeted by immunotherapy, you may just get immunotherapy alone,” Dr. Stiles tells SurvivorNet.
Immunotherapy uses the power of your own immune system to recognize cancer cells and kill them. It has been especially successful in late stage lung cancer, but Dr. Stiles says that clinical trials are developing so it can treat early-stage lung cancer as well.
Learn more about SurvivorNet's rigorous medical review process.